Intercell: Restructuring Is Progressing

Published: August 16, 2011; 10:54 · (Vindobona)

Sales of the company’s only product on the market increased by 85% in the first six months of the year. Net loss was down 44.2%.

Intercell: Restructuring Is Progressing / Picture: © Intercell

The listed vaccine producer Intercell on Tuesday presented results for the second quarter and the first half of 2011. Revenue increased by 27.5% to € 18.38m from January to June. Net loss was reduced by 44.2% and amounted to € 12.9m which is still 70% of revenue.

Sales of the company’s only product currently on the market, a vaccine to prevent Japanese Encephalitis…

This article includes a total of 192 words.

or Log In

Fast News Search

Join us to succeed in Vienna! Sign up to read articles for free and to get personalized updates on the events that interest you.

Intercell: Restructuring Is Progressing

Sales of the company’s only product on the market increased by 85% in the first six months of the year. Net loss was down 44.2%.

Join us to succeed in Vienna!
Sign up to read articles for free and to get personalized updates on the events that interest you.